Gastrointestinal stability of therapeutic anti-TNF α IgG1 monoclonal antibodies

International Journal of Pharmaceutics

Volumn 502, Issue 1-2, 2016, Pages 181-187

  Yadav, Vipul ^a   Varum, Felipe ^b   Bravo, Roberto ^b   Furrer, Esther ^b   Basit, Abdul W ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b Tillotts Pharma UK Ltd   (Switzerland)

Author keywords

Adalimumab; Gastrointestinal stability; Infliximab; Monoclonal antibodies; Oral delivery; Tumor necrosis factor alpha (TNF )

Indexed keywords

ADALIMUMAB; CHYMOTRYPSIN; ELASTASE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; INFLIXIMAB; TRYPSIN; ALPHA-CHYMOTRYPSIN; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; PANCREATIC ELASTASE; PANCREATIN; TUMOR NECROSIS FACTOR;

ARTICLE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG STABILITY; GASTROINTESTINAL TRACT; HUMAN; HUMAN TISSUE; INTESTINE FLUID; PRIORITY JOURNAL; SMALL INTESTINE; STOMACH JUICE; CHEMISTRY; COLON; FECES; IMMUNOLOGY; INTESTINAL SECRETIONS; METABOLISM;

ADALIMUMAB; ANTIRHEUMATIC AGENTS; CHYMOTRYPSIN; COLON; FECES; GASTRIC JUICE; HUMANS; IMMUNOGLOBULIN G; INFLIXIMAB; INTESTINAL SECRETIONS; PANCREATIC ELASTASE; PANCREATIN; TRYPSIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84959517229     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2016.02.014     Document Type: Article

References (31)

1. A.W. Basit, J.M. Newton, and L.F. Lacey Susceptibility of the H2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora Int. J. Pharm. 237 2002 23 33
2. P.M. Blum, D.L. Phelps, B.J. Ank, H.J. Krantman, and E.R. Stiehm Survival of oral human immune serum globulin in the gastrointestinal tract of low birth weight infants Pediatr. Res. 15 1981 1256 1260
3. A.S. Borde, E.M. Karlsson, K. Andersson, K. Bjorhall, H. Lennernas, and B. Abrahamsson Assessment of enzymatic prodrug stability in human, dog and simulated intestinal fluids Eur. J. Pharm. Biopharm. 80 2012 630 637
4. R.J. Brezski, A. Oberholtzer, B. Strake, and R.E. Jordan The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge MAbs 3 2011 558 567
5. A. Diakidou, M. Vertzoni, K. Goumas, E. Soderlind, B. Abrahamsson, J. Dressman, and C. Reppas Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults Pharm. Res. 26 2009 2141 2151
6. H. Hatta, K. Tsuda, S. Akachi, M. Kim, T. Yamamoto, and T. Ebina Oral passive immunization effect of anti-human rotavirus IgY and its behavior against proteolytic enzymes Biosci. Biotechnol. Biochem. 57 1993 1077 1081
7. R. Hirsch, J.A. Bluestone, L. DeNenno, and R.E. Gress Anti-CD3 F(ab') 2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb Transplantation 49 1990 1117 1123
8. S.A. Hughes, P.R. Shewry, G.R. Gibson, B.V. McCleary, and R.A. Rastall In vitro fermentation of oat and barley derived beta-glucans by human faecal microbiota FEMS Microbiol. Ecol. 64 2008 482 493
9. G. Hussack, T. Hirama, W. Ding, R. Mackenzie, and J. Tanha Engineered single-domain antibodies with high protease resistance and thermal stability PLoS One 6 2011 e28218
10. A.S. Inglis Cleavage at aspartic acid Methods Enzymol. 91 1983 324 332
11. B. Keil Specificity of Proteolysis 1992 Springer-Verlag 335
12. J. Lin, D. Ziring, S. Desai, S. Kim, M. Wong, Y. Korin, J. Braun, E. Reed, D. Gjertson, and R.R. Singh TNFalpha blockade in human diseases: An overview of efficacy and safety Clin. Immunol. 126 2008 13 30
13. A. Lindahl, A.L. Ungell, L. Knutson, and H. Lennernas Characterization of fluids from the stomach and proximal jejunum in men and women Pharm. Res. 14 1997 497 502
14. R.I. Mahato, A.S. Narang, L. Thoma, and D.D. Miller Emerging trends in oral delivery of peptide and protein drugs Crit. Rev. Ther. Drug Carrier Syst. 20 2003 153 214
15. P. Miheller, L.S. Kiss, K. Lorinczy, and P.L. Lakatos Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: Are they ready for everyday clinical use? Expert Opin. Biol. Ther. 12 2012 179 192
16. N. Roos, S. Mahe, R. Benamouzig, H. Sick, J. Rautureau, and D. Tome 15N-labeled immunoglobulins from bovine colostrum are partially resistant to digestion in human intestine J. Nutr. 125 1995 1238 1244
17. W.J. Sandborn, S.D. Lee, C. Randall, A. Gutierrez, D.A. Schwartz, S. Ambarkhane, C. Kayhan, B. Pierre-Louis, S. Schreiber, and G.R. Lichtenstein Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study Aliment. Pharmacol. Ther. 40 2014 903 916
18. N. Scheinfeld A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab J. Dermatolog. Treat. 15 2004 280 294
19. I. Sekirov, S.L. Russell, L.C. Antunes, and B.B. Finlay Gut microbiota in health and disease Physiol. Rev. 90 2010 859 904
20. M. Shimizu, R.C. Fitzsimmons, and S. Nakai Anti-E. coli lmmunoglobulin Y isolated from egg yolk of immunized chickens as a potential food ingredient J. Food Sci. 53 1988 1360 1368
21. A.L. Smart, S. Gaisford, and A.W. Basit Oral peptide and protein delivery: Intestinal obstacles and commercial prospects Expert Opin. Drug Deliv. 11 2014 1323 1335
22. T. Sousa, R. Paterson, V. Moore, A. Carlsson, B. Abrahamsson, and A.W. Basit The gastrointestinal microbiota as a site for the biotransformation of drugs Int. J. Pharm. 363 2008 1 25
23. T. Sousa, V. Yadav, V. Zann, A. Borde, B. Abrahamsson, and A.W. Basit On the colonic bacterial metabolism of azo-bonded prodrugsof 5-aminosalicylic acid J. Pharm. Sci. 103 2014 3171 3175
24. C. Tannergren, A. Borde, C. Borestrom, B. Abrahamsson, and A. Lindahl Evaluation of an in vitro faecal degradation method for early assessment of the impact of colonic degradation on colonic absorption in humans Eur. J. Pharm. Sci. 57 2014 200 206
25. J. Vlasak, and R. Ionescu Fragmentation of monoclonal antibodies MAbs 3 2011 253 263
26. W. Wang, S. Singh, D.L. Zeng, K. King, and S. Nema Antibody structure, instability, and formulation J. Pharm. Sci. 96 2007 1 26
27. J. Wang, V. Yadav, A.L. Smart, S. Tajiri, and A.W. Basit Stability of peptide drugs in the colon Eur. J. Pharm. Sci. 78 2015 31 36
28. J. Wang, V. Yadav, A.L. Smart, S. Tajiri, and A.W. Basit Toward oral delivery of biopharmaceuticals: An assessment of the gastrointestinal stability of 17 peptide drugs Mol. Pharm. 12 2015 966 973
29. M.A. Willrich, D.L. Murray, and M.R. Snyder Tumor necrosis factor inhibitors: Clinical utility in autoimmune diseases Transl. Res. 165 2015 270 282
30. V. Yadav, S. Gaisford, H.A. Merchant, and A.W. Basit Colonic bacterial metabolism of corticosteroids Int. J. Pharm. 457 2013 268 274
31. O. de Rham, and H. Isliker Proteolysis of bovine immunoglobulins Int. Arch. Allergy Appl. Immunol. 55 1977 61 69